JP7633930B2 - 抗癌ワクチンのための共有腫瘍抗原としてのｈｅｒｖ－ｋ由来抗原 - Google Patents

抗癌ワクチンのための共有腫瘍抗原としてのｈｅｒｖ－ｋ由来抗原 Download PDF

Info

Publication number
JP7633930B2
JP7633930B2 JP2021512759A JP2021512759A JP7633930B2 JP 7633930 B2 JP7633930 B2 JP 7633930B2 JP 2021512759 A JP2021512759 A JP 2021512759A JP 2021512759 A JP2021512759 A JP 2021512759A JP 7633930 B2 JP7633930 B2 JP 7633930B2
Authority
JP
Japan
Prior art keywords
seq
peptide
peptides
composition
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021512759A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021536479A (ja
Inventor
ドゥピル ステファーヌ
トノン ロリー
コー クリストフ
ボナベンチュラ パオラ
バラドー ジェニー
Original Assignee
サントル レオン ベラール
ユニベルシテ クロード ベルナール リヨン プルミエ
サントル ナシオナル ドゥ ラ ルシェルシェ サイアンティフィク
アンスティテュ ナシオナル ドゥ ラ サントゥ エ ドゥ ラ ルシェルシェ メディカル（イーエヌエスエーエールエム）
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サントル レオン ベラール, ユニベルシテ クロード ベルナール リヨン プルミエ, サントル ナシオナル ドゥ ラ ルシェルシェ サイアンティフィク, アンスティテュ ナシオナル ドゥ ラ サントゥ エ ドゥ ラ ルシェルシェ メディカル（イーエヌエスエーエールエム） filed Critical サントル レオン ベラール
Publication of JP2021536479A publication Critical patent/JP2021536479A/ja
Priority to JP2024155019A priority Critical patent/JP2025003964A/ja
Application granted granted Critical
Publication of JP7633930B2 publication Critical patent/JP7633930B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/34—Antigenic peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2021512759A 2018-09-06 2019-09-06 抗癌ワクチンのための共有腫瘍抗原としてのｈｅｒｖ－ｋ由来抗原 Active JP7633930B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024155019A JP2025003964A (ja) 2018-09-06 2024-09-09 抗癌ワクチンのための共有腫瘍抗原としてのｈｅｒｖ－ｋ由来抗原

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18306173.8 2018-09-06
EP18306173 2018-09-06
PCT/EP2019/073883 WO2020049169A1 (en) 2018-09-06 2019-09-06 Herv-k-derived antigens as shared tumor antigens for anti-cancer vaccine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024155019A Division JP2025003964A (ja) 2018-09-06 2024-09-09 抗癌ワクチンのための共有腫瘍抗原としてのｈｅｒｖ－ｋ由来抗原

Publications (2)

Publication Number Publication Date
JP2021536479A JP2021536479A (ja) 2021-12-27
JP7633930B2 true JP7633930B2 (ja) 2025-02-20

Family

ID=63683819

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021512759A Active JP7633930B2 (ja) 2018-09-06 2019-09-06 抗癌ワクチンのための共有腫瘍抗原としてのｈｅｒｖ－ｋ由来抗原
JP2024155019A Pending JP2025003964A (ja) 2018-09-06 2024-09-09 抗癌ワクチンのための共有腫瘍抗原としてのｈｅｒｖ－ｋ由来抗原

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024155019A Pending JP2025003964A (ja) 2018-09-06 2024-09-09 抗癌ワクチンのための共有腫瘍抗原としてのｈｅｒｖ－ｋ由来抗原

Country Status (12)

Country Link
US (1) US20210330774A1 (enExample)
EP (1) EP3846839A1 (enExample)
JP (2) JP7633930B2 (enExample)
KR (1) KR20210055725A (enExample)
CN (1) CN112867502A (enExample)
AU (1) AU2019334676B2 (enExample)
BR (1) BR112021004244A2 (enExample)
CA (1) CA3111663A1 (enExample)
IL (1) IL281253B2 (enExample)
MX (1) MX2021002519A (enExample)
SG (1) SG11202102290RA (enExample)
WO (1) WO2020049169A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202000006973A1 (it) * 2020-04-02 2021-10-02 Istituto Naz Tumori Irccs Fondazione G Pascale Antigeni herv tumore-specifici e loro uso nella immunoterapia del cancro
US11791123B2 (en) 2021-04-29 2023-10-17 Electronics And Telecommunications Research Institute X-ray tube
US20250147046A1 (en) 2022-01-25 2025-05-08 Ervimmune New method for identifying herv-derived epitopes
WO2023242343A1 (en) 2022-06-15 2023-12-21 Immunoscape Pte. Ltd. Human t cell receptors specific for antigenic peptides derived from mitogen-activated protein kinase 8 interacting protein 2 (mapk8ip2), epstein-barr virus or human endogenous retrovirus, and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005535308A (ja) 2002-06-13 2005-11-24 カイロン コーポレイション Ｈｍｌ−２ポリペプチド発現用ベクター
WO2006103562A2 (en) 2005-03-30 2006-10-05 Centre National De La Recherche Scientifique (Cnrs) Endogenous retrovirus and proteins encoded by env gene as a target for cancer treatment
JP2009544614A (ja) 2006-07-21 2009-12-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ヒト内在性レトロウイルスポリペプチド組成物およびその使用法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4866034A (en) 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US4950645A (en) 1988-07-08 1990-08-21 Immunotherapeutics, Inc. Composition for macrophage activation
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
JP2004535765A (ja) * 2000-12-07 2004-12-02 カイロン コーポレイション 前立腺癌においてアップレギュレートされた内因性レトロウイルス
WO2003106634A2 (en) * 2002-06-13 2003-12-24 Chiron Corporation Vectors for expression of hml-2 polypeptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005535308A (ja) 2002-06-13 2005-11-24 カイロン コーポレイション Ｈｍｌ−２ポリペプチド発現用ベクター
WO2006103562A2 (en) 2005-03-30 2006-10-05 Centre National De La Recherche Scientifique (Cnrs) Endogenous retrovirus and proteins encoded by env gene as a target for cancer treatment
JP2009544614A (ja) 2006-07-21 2009-12-17 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ヒト内在性レトロウイルスポリペプチド組成物およびその使用法

Also Published As

Publication number Publication date
AU2019334676A1 (en) 2021-04-01
IL281253B1 (en) 2024-03-01
JP2021536479A (ja) 2021-12-27
JP2025003964A (ja) 2025-01-14
IL281253B2 (en) 2024-07-01
KR20210055725A (ko) 2021-05-17
US20210330774A1 (en) 2021-10-28
AU2019334676B2 (en) 2025-06-05
IL281253A (en) 2021-04-29
CA3111663A1 (en) 2020-03-12
CN112867502A (zh) 2021-05-28
WO2020049169A1 (en) 2020-03-12
BR112021004244A2 (pt) 2021-05-25
MX2021002519A (es) 2021-06-18
EP3846839A1 (en) 2021-07-14
SG11202102290RA (en) 2021-04-29

Similar Documents

Publication Publication Date Title
JP2025003964A (ja) 抗癌ワクチンのための共有腫瘍抗原としてのｈｅｒｖ－ｋ由来抗原
KR101592855B1 (ko) 암 백신 조성물
AU2013316679B2 (en) Cell penetrating peptides
KR101284237B1 (ko) Ｂｃｌ-2 패밀리에 속한 단백질들, 그들의 단편들 및 암 환자에 대한 그들의 용도
EP1548032B9 (en) Kdr peptides and vaccines comprising the same
KR20220163523A (ko) 신생항원 및 이것의 사용 방법
US10688165B2 (en) Medicament for use in a method of inducing or extending a cellular cytotoxic immune response
JP6619788B2 (ja) Ｈｉｖ用の免疫学的組成物
JP5065273B2 (ja) Ｈｌａ−ａ２４分子結合性ｋｉｆ由来ペプチド
JP2011506497A5 (enExample)
WO2019102265A1 (en) Peptide displaying bacteriophage nanoparticles and related compositions and methods
KR20150084060A (ko) 암의 예방 및 치료용 msi-특이적 프레임쉬프트 펩티드(fsp)
WO2011038002A1 (en) Immunogenic epitopes as targets for universal cancer vaccines
JP2016028025A (ja) がんの予防及び治療のためのｍｓｉ特異的なフレームシフトペプチド（ｆｓｐ）
JP5890769B2 (ja) がんの予防及び治療のためのｍｓｉ特異的なフレームシフトペプチド（ｆｓｐ）
KR20180135629A (ko) ＰＬＫ１ 단백질에 대한 항원―특이 Ｔ 세포 면역반응을 유도하는 ＨＬＡ―Ａ２ 아형―특이 ＰＬＫｌ―유래 항원결정기
JP4443202B2 (ja) Ｃｄ４陽性ｔ細胞に認識されるペプチド
RU2805196C2 (ru) Неоантигены и их применение
RU2773273C2 (ru) Неоантигены и способы их использования
JP2023515850A (ja) 腫瘍免疫増強剤、その調製方法および適用
US20070237790A1 (en) Identification of gene sequences and proteins involved in vaccinia virus dominant T cell epitopes
EA048578B1 (ru) Агрегаты asc в иммунотерапии рака

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220805

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230710

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230808

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240207

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240909

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240911

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20241002

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241224

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250207

R150 Certificate of patent or registration of utility model

Ref document number: 7633930

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150